XOMA (XOMA) Rating Reiterated by HC Wainwright
HC Wainwright reissued their buy rating on shares of XOMA (NASDAQ:XOMA) in a report issued on Friday morning. HC Wainwright currently has a $49.00 price objective on the biotechnology company’s stock.
“Valuation disconnect continues even when considering a limited set of current assets. Regarding our valuation of XOMA we believe that the current share price is currently disconnected from the underlying value of even just its opportunity from Novartis (NVS; not rated) partnered assets, led by canakinumab (Ilaris).”,” the firm’s analyst commented.
A number of other equities research analysts have also recently commented on the company. Wedbush reissued an outperform rating and set a $33.00 price target on shares of XOMA in a report on Wednesday, August 8th. Zacks Investment Research cut XOMA from a buy rating to a hold rating in a report on Saturday, July 21st. S&P Equity Research cut their price objective on XOMA from $18.74 to $16.26 in a research report on Tuesday, August 14th. ValuEngine lowered XOMA from a hold rating to a sell rating in a research report on Friday, September 7th. Finally, TheStreet upgraded XOMA from a d rating to a c- rating in a research report on Tuesday, June 12th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $31.32.
XOMA (NASDAQ:XOMA) last posted its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.03). The business had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.57 million. XOMA had a net margin of 43.55% and a return on equity of 379.39%. analysts predict that XOMA will post -0.89 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of the company. Northern Trust Corp grew its position in shares of XOMA by 308.6% during the second quarter. Northern Trust Corp now owns 68,200 shares of the biotechnology company’s stock valued at $1,424,000 after purchasing an additional 51,510 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of XOMA by 50.7% during the second quarter. Bank of New York Mellon Corp now owns 35,661 shares of the biotechnology company’s stock valued at $745,000 after purchasing an additional 12,002 shares in the last quarter. Dynamic Technology Lab Private Ltd grew its position in shares of XOMA by 57.6% during the second quarter. Dynamic Technology Lab Private Ltd now owns 20,112 shares of the biotechnology company’s stock valued at $420,000 after purchasing an additional 7,349 shares in the last quarter. ClariVest Asset Management LLC grew its position in shares of XOMA by 25.0% during the second quarter. ClariVest Asset Management LLC now owns 23,500 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 4,700 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of XOMA during the second quarter valued at about $568,000. Hedge funds and other institutional investors own 43.60% of the company’s stock.
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Featured Story: How much money do you need to begin day trading?
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.